WARSAW, Ind., May 1, 2015 (GLOBE NEWSWIRE) -- Nextremity Solutions, Inc., a medical device company in the orthopedic industry, has announced that it recently oversold it's initial $3 million preferred stock offering. The offering began on February 2015 and closed on March 31, 2015. This offering was open to current investors and new employees, which indicates that investors see value in the company with its planned objectives that are outlined in the company's business plan.
Nextremity Solutions, Inc. is one of a few orthopedic companies that consider itself a pure-play foot and ankle company. The company's current product offerings include advanced technological solutions for various foot pathologies, such as the Nextra® Hammertoe Correction System, the Re+Line® Bunion Correction System, and their most recently launched MSPTM Metatarsal Shortening System.
"Our plans are to increase our product portfolio greatly within the next year as we develop more products that cover various pathologies in the foot. This capital raise positions Nextremity Solutions to execute our planned objectives, benefiting our shareholders with accelerated company growth," said Nick A. Deeter, CEO and Chairman of the Board of Nextremity Solutions, Inc.
Nextremity Solutions, Inc. plans on releasing 10 product systems in 2015-2016, as well as additional educational opportunities that foster surgeon-to-surgeon relationships.
About Nextremity Solutions, Inc.
Nextremity Solutions, Inc. is a privately held medical device company offering innovative solutions and approaches to foot and ankle surgical intervention. The Company's procedure-ready, sterile implant systems for the correction of foot and ankle pathologies include uniquely precise, proprietary technology designed to achieve repeatable and superior clinical outcomes.
For further information, visit www.nextremitysolutions.com or call Dave Temple, Director of Marketing & Corporate Communications at 574-635-3023.
CONTACT: Dave Temple Director of Marketing & Corporate Communications 574-635-3023Source:Nextremity Solutions, Inc.